79% NUVA revenue from MAS in Q3. Significant portion of this revenue was from Neuro-Vision monitoring platform disposables and hospital use fees. Medtronic, with a 500+ strong sales force has released NIM spinal monitoring. NIM will compete well with NUVA at much lower cost per procedure to the hospital. Medtronic sales force will leverage their strong relationships and hospital contracts to sell NIM. Also, NUVA has strongly emphasized per case incremental surgeon reimbursement when selling the Neuro-Vision concept to surgeons. Recent CCI edits regarding intra-operative neuro monitoring are likely to eliminate commercial carrier payment to surgeons in the very near future.
NUVA touting new pedicle screw system, but much of distribution network is Stryker. How long will Stryker allow their distributors to sell a competitive product? I could go on, but will suffice to say that while NUVA has a talented management team that can sell the "sizzle", if you knew the market like I do, you would realize that there is minimal meat on the grill. Get out now.
Excellent comments, I was thinking of buying based on the following: I thought much of their sales was from Maxecces and that with a launch of a pedicle system if they converted just 25% of Maxecces cases to their screws they would double sales, (screws are 4x the price of any maxecces disposables, I assume)
Spinal concept is kicking on pathfinder if NUVA's max + pedicle is any where as good they could suprise on the up side.
Please comment. Actual sales forecasts would be great.